TNFSF12-TNFSF13
Tumor necrosis factor (ligand) superfamily, member 12-member 13, also known as TNFSF12-TNFSF13, is a human gene.[1]
This gene belongs to the tumor necrosis factor superfamily (TNFSF). It encodes a hybrid protein composed of the cytoplasmic and transmembrane domains of the family member 12 fused to the C-terminal domain of the family member 13. The hybrid protein is membrane anchored and presents the receptor-binding domain of the family member 13 at the cell surface. It stimulates cycling in T-lymphoma and B-lymphoma cell lines. The mRNA transcript is expressed and translated in primary T cells and monocytes.[1]
References
Further reading
- Hahne M, Kataoka T, Schröter M, et al. (1998). “APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth”. J. Exp. Med. 188 (6): 1185–90. doi:10.1084/jem.188.6.1185. PMC 2212534. PMID 9743536.
- Kelly K, Manos E, Jensen G, et al. (2000). “APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death”. Cancer Res. 60 (4): 1021–7. PMID 10706119.
- Wu Y, Bressette D, Carrell JA, et al. (2001). “Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS”. J. Biol. Chem. 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.
- Yu G, Boone T, Delaney J, et al. (2001). “APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity”. Nat. Immunol. 1 (3): 252–6. doi:10.1038/79802. PMID 10973284.
- Gallouzi IE, Brennan CM, Steitz JA (2001). “Protein ligands mediate the CRM1-dependent export of HuR in response to heat shock”. RNA. 7 (9): 1348–61. doi:10.1017/S1355838201016089. PMC 1370177. PMID 11565755. (Retracted. If this is an intentional citation to a retracted paper, please replace
{{Retracted}}with{{Retracted|intentional=yes}}.) - López-Fraga M, Fernández R, Albar JP, Hahne M (2002). “Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase”. EMBO Rep. 2 (10): 945–51. doi:10.1093/embo-reports/kve198. PMC 1084076. PMID 11571266.
- Roschke V, Sosnovtseva S, Ward CD, et al. (2002). “BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases”. J. Immunol. 169 (8): 4314–21. doi:10.4049/jimmunol.169.8.4314. PMID 12370363.
- Pradet-Balade B, Medema JP, López-Fraga M, et al. (2002). “An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK–APRIL fusion protein”. EMBO J. 21 (21): 5711–20. doi:10.1093/emboj/cdf565. PMC 131062. PMID 12411489.
- Hendriks J, Planelles L, de Jong-Odding J, et al. (2005). “Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation”. Cell Death Differ. 12 (6): 637–48. doi:10.1038/sj.cdd.4401647. PMID 15846369.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH